rs2811712 — CDKN2BAS
Regulatory variant in the ANRIL long non-coding RNA at the 9p21.3 locus that influences CDKN2B expression and functional aging; the G allele is protective against physical impairment with age
Details
- Gene
- CDKN2BAS
- Chromosome
- 9
- Risk allele
- A
- Clinical
- Risk Factor
- Evidence
- Moderate
Population Frequency
Category
Longevity & AgingSee your personal result for CDKN2BAS
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
ANRIL and Functional Aging — The 9p21.3 Longevity Locus
A single stretch of chromosome 9 — the 9p21.3 locus — is the most consistently
replicated region in genome-wide association studies for age-related disease.
Coronary artery disease, type 2 diabetes, glioma, melanoma, and now physical
aging have all been linked to variation here. At the heart of the locus sits
ANRIL (antisense non-coding RNA in the INK4 locus)11 ANRIL (antisense non-coding RNA in the INK4 locus)
Also designated CDKN2BAS or CDKN2B-AS1 — a long non-coding RNA transcribed antisense to the CDKN2A/CDKN2B tumor suppressor genes,
a molecular rheostat for cellular senescence.
rs2811712 is a tag SNP within ANRIL that was identified in a landmark study as
associated with physical function in older people22 associated with physical function in older people
Melzer D et al. A common variant of the p16INK4a genetic region is associated with physical function in older people. Mech Ageing Dev. 2007.
The G allele — carried by roughly one in five people of European ancestry — is
associated with substantially better preserved physical function in old age, while
the common A allele is the risk-conferring genotype.
The Mechanism
The 9p21.3 locus contains three protein-coding genes — CDKN2A (encoding
p16INK4a and p14ARF), CDKN2B (encoding p15INK4b), and MTAP — all flanked and
overlapped by ANRIL. p16INK4a and p15INK4b are
cyclin-dependent kinase inhibitors33 cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4/6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint
that drive cellular senescence: as cells age and accumulate damage, p16 levels
rise, arresting the cell cycle and converting cells into
senescent "zombie" cells44 senescent "zombie" cells
Senescent cells stop dividing but remain metabolically active, secreting pro-inflammatory cytokines (the SASP — senescence-associated secretory phenotype) that damage neighboring tissue
that fuel the chronic inflammation underlying age-related functional decline.
ANRIL regulates CDKN2A/CDKN2B expression in cis through Polycomb group protein recruitment, particularly the PRC2 complex, which methylates histone H3K27 to silence the INK4 locus. In proliferating cells, ANRIL keeps senescence genes suppressed; as ANRIL expression shifts with aging or genetic variation, the balance tips toward elevated p16 and p15, accelerating the senescent phenotype. rs2811712 is an eQTL for CDKN2B expression: studies show that variation here correlates with altered ANRIL isoform abundance and downstream CDKN2B levels, providing a molecular pathway from genotype to functional aging phenotype.
The Evidence
The primary association was established by
Melzer et al. (2007)55 Melzer et al. (2007)
A common variant of the p16INK4a genetic region is associated with physical function in older people. Mechanisms of Ageing and Development.
across three independent European cohorts totaling 3,372 elderly individuals (EPIC-Norfolk sets 1 and 2 plus InCHIANTI). Severely limited physical function — defined by performance-based tests of walking speed, chair stand, and balance — was present in 15.0% of AA homozygotes versus 7.0% of GG homozygotes, nearly half the rate. The per-A-allele odds ratio was 1.48 (95% CI 1.17–1.88, p = 0.001), adjusted for age, sex, and study. The association held across all three cohorts tested independently, including a trend in the Iowa-EPESE cohort (n=419, p=0.079 one-sided), making this one of the first robust genetic associations for functional aging specifically.
A Han Chinese case-control study
Wu et al. (2012)66 Wu et al. (2012)
Heterozygote genotypes at rs2222823 and rs2811712 SNP loci are associated with cerebral small vessel disease in Han Chinese population
found the heterozygote genotype at rs2811712 was associated with OR 1.75 (CI 1.13–2.71, p=0.004) for cerebral small vessel disease — consistent with the broader pattern that the A (risk) allele at this locus impairs vascular and neurological aging beyond musculoskeletal function.
The broader 9p21.3 locus literature confirms that ANRIL variants influence
CDKN2B expression and cellular senescence77 CDKN2B expression and cellular senescence
SNPs here show inverse effects on ANRIL and CDKN2B expression, supporting a role of antisense transcription in regulating senescence pathways,
with the risk alleles generally increasing ANRIL expression in ways that paradoxically reduce appropriate p16/p15 upregulation in vascular cells, impairing the normal senescence response to damage. This locus is the strongest genetic signal for coronary artery disease in Europeans (OR ~1.3 per risk allele), though rs2811712 itself does not independently associate with CAD — its primary documented phenotype is functional physical aging.
Practical Actions
For carriers of two A alleles (AA), the evidence supports a targeted approach to slowing the accumulation of senescent cells and their inflammatory secretome. The most directly relevant interventions for the CDKN2B/p16 axis include:
- Senolytic compounds: Fisetin (a flavonoid concentrated in strawberries and onions) and quercetin have demonstrated senolytic activity in human studies — selectively promoting apoptosis in p16-expressing senescent cells. Intermittent high-dose fisetin (≥500 mg/day for 2–3 days per month) reduced senescent cell burden and SASP markers in published clinical data.
- Cardiovascular monitoring: The 9p21.3 region is the strongest common genetic locus for coronary artery disease. While rs2811712 itself does not independently associate with CAD, it tags a haplotype block where other risk variants reside. AA carriers should ensure thorough cardiovascular risk assessment.
- Strength and resistance training: p16-driven muscle senescence contributes directly to sarcopenia (age-related muscle loss) — the leading mediator of physical impairment in older adults. Resistance training specifically reduces senescent cell burden in skeletal muscle and preserves muscle fiber function through mechanisms that parallel the CDKN2B pathway.
AG carriers carry one protective G allele: physical function risk is intermediate, and the same principles apply with moderated urgency.
Interactions
rs10757278 and rs1333049 (9p21.3 haplotype): These are the primary CAD-associated SNPs at the 9p21 locus, in moderate-to-high LD with rs2811712. If you carry the risk haplotype at rs10757278 (G allele) in addition to AA at rs2811712, the combined burden on ANRIL/CDKN2B regulation is likely greater than either marker alone. The 9p21.3 block spans ~58 kb and multiple SNPs contribute to its overall phenotypic effect.
rs564398 (upstream of CDKN2A): Another 9p21 tag SNP associated with type 2 diabetes and glioma risk, which shares the ANRIL regulatory context. Combined risk at rs2811712 and rs564398 may implicate broader ANRIL dysregulation beyond the physical aging phenotype.
Genotype Interpretations
What each possible genotype means for this variant:
Two protective G alleles — substantially reduced functional aging risk
The GG genotype at rs2811712 represents the most favorable common variant state at this ANRIL regulatory locus. Two G alleles tip the ANRIL/CDKN2B balance toward reduced senescent cell accumulation in muscle and vascular tissue, translating into preserved physical function across multiple independent elderly cohorts. The association replicated across EPIC-Norfolk and InCHIANTI with consistent direction and magnitude, and the biological mechanism through ANRIL-mediated CDKN2B regulation provides a plausible pathway from genotype to phenotype.
This protective signal does not eliminate aging-related risk — lifestyle, fitness, cardiovascular risk factors, and other genetic variants all contribute — but it does indicate a meaningful genetic tailwind for physical function in later decades.
One protective G allele — intermediate functional aging risk
The G allele at rs2811712 appears to confer a dosage-dependent protective effect on physical function in aging. One copy shifts the ANRIL regulatory balance toward reduced senescent cell accumulation in muscle and vascular tissue compared to AA, though the full protective effect requires two copies. The additive inheritance pattern documented in the study (per-allele OR 1.48) means one allele confers roughly the square root of the two-allele protective benefit.
Your one G allele is meaningful — the risk increment above the GG baseline is approximately half what AA carriers face. Preventive strategies remain important, particularly as you age past 60 when senescent cell burden rises steeply.
Increased susceptibility to age-related physical impairment
The 9p21.3 locus where rs2811712 sits is one of the most studied regions in human genetics, linking ANRIL expression to the cyclin-dependent kinase inhibitors p16INK4a and p15INK4b. These proteins enforce cell cycle arrest in damaged cells — a necessary safeguard against cancer, but one that accelerates tissue aging when too many cells become senescent. The AA genotype at rs2811712 is associated with a regulatory state that, over decades, tips the balance toward greater senescent cell burden and the chronic low-grade inflammation (inflammaging) that drives physical decline.
The association with physical function was replicated across three independent European cohorts (EPIC-Norfolk sets 1 and 2, InCHIANTI), and confirmed in Han Chinese populations for cerebral small vessel disease, suggesting the biology generalizes across ancestries.
No intervention can eliminate genetic risk, but senescent cell burden is a modifiable biological target. Senolytic compounds, cardiovascular monitoring, and resistance training are the most evidence-grounded strategies for this specific locus.